WVE WAVE Life Sciences

WAVE Life Sciences to Present at Upcoming Investor Conferences

WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing targeted therapies for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will be participating at the following upcoming investor conferences:

  • Jefferies 2017 Global Healthcare Conference – WAVE Company Presentation

    Wednesday, June 7th at 1:30 P.M. ET – New York
  • The JMP Securities Life Science Conference – Company Panel Discussion: Neuromuscular Disorders

    Tuesday, June 20th at 2:00 P.M. ET – New York

A live webcast of the WAVE company presentation at the Jefferies 2017 Global Healthcare Conference will be available on the investor relations page of the WAVE Life Sciences corporate website at http://ir.wavelifesciences.com. A replay will remain archived on the corporate website for a limited time.

About WAVE Life Sciences

At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize rationally redesigned nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit www.wavelifesciences.com.

EN
06/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on WAVE Life Sciences

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Wave Life Sciences Reports Second Quarter 2025 Financial Results and P...

Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg) RestorAATion-2 clinical data from complete 200 mg single and multidose dose cohorts remain on track for 3Q 2025; data from complete 400 mg single dose cohort remain on track for fall 2025 ...

Yun Zhong
  • Yun Zhong

AATD Multi-Dose Data Should Be Good; Could Be Available Soon

Initial INHBE data in 2H25 Will be the Next Catalyst. WVE expects to report safety and tolerability, as well as biomarker data that could reflect healthy weight loss from the placebo-controlled study (NCT06842186). We would expect positive stock reaction if the data show dose-dependent knockdown of

ResearchPool Subscriptions

Get the most out of your insights

Get in touch